Physician profile
Moshe Hasbani
NPI 1225022973
$9,507.87
in general payments reported to CMS, 2019-2025
59 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 75% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,784 · 2020: $726 · 2021: $555 · 2022: $1,225 · 2023: $959 · 2024: $1,379 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,119 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,222.19 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $786.13 | 2019-2025 | Crexont, Rytary |
| Ucb, INC. | $516.39 | 2019-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Amgen INC. | $484.88 | 2019-2025 | Uplizna |
| Biogen, INC. | $472.41 | 2019-2022 | |
| Emd Serono, INC. | $451.94 | 2019-2025 | Mavenclad |
| Abbvie INC. | $370.15 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $331.36 | 2020-2024 | Austedo Xr, Austedo |
| Genzyme Corporation | $320.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $243.60 | 2021-2024 | Spravato |
| Eisai INC. | $229.24 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $227.56 | 2020-2025 | Acthar |
| Tanabe Pharma America, INC. | $225.04 | 2020-2025 | Radicava |
| Alexion Pharmaceuticals, INC. | $203.09 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $195.87 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Hasbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.